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1. Introduction
Allergic diseases are manifested in susceptible individual by exposure to proteins named
allergens that induce an immune response mediated by IgE antibody. Numerous allergens
from different sources such as plants, insects, mites and mammals have been obtained as
recombinant molecules by molecular cloning. These types of molecules have shown molecular,
functional and immunological properties similar to the corresponding natural allergens and,
therefore, could be used for in vitro and in vivo diagnosis test of allergy. An important step
was done with the development of variants of allergens with reduced allergenicity and
preserved immunogenicity, which paved the way toward its rational use in allergen specific
immunotherapy to treat allergies. Few of the allergens cloned have been developed to a stage
at which they are suitable for use in clinical studies. However, today the academic and scientific
communities note a broad and important activity to offer in the near future preparations with
enhanced clinical efficacy and safety. In this work, basic aspects and experimental and clinical
results of this process are presented.
2. Progress in the molecular cloning and production of allergens
The molecular cloning has provided a practical and efficient way to obtain highly purified
molecules for different purposes; in the biomedical sciences this is evident by the increasing
amount of biological products, obtained by recombinant DNA technology, which are com‐
mercially available for diagnosis and treatment of different diseases, as well as the wide variety
of reagents for basic research. The era of molecular cloning of allergen molecules was initiated
in 1988 with the report of a cDNA clone coding for the allergen Der p 1 isolated from a cDNA
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library of the house dust mite Dermatophagoides pteronyssinus, screened with rabbit anti -Der p
1 antiserum [1, 2]. Latter, Tovey, E.R et al. [3], using sera from allergic individuals for screening
a mite cDNA library also isolated a clone of Der p 1. This strategy was useful to explore the
whole spectrum of IgE binding proteins in a natural source and to isolate positive clones to
express the molecules [4, 5]. The development and optimization of technology based on the
polymerase chain reaction (PCR), have given an important impulse to cloning and identifica‐
tion of new allergens. PCR can be applied to screen cDNA library and amplify specific clones,
or to obtain by RT- PCR the nucleotide sequence coding for specific allergens and then cloning
in an appropriate vector for expression [6-10]. The numerous nucleotide sequences of allergens
reported in data bank have facilitated the isolation of new allergens from RNA material using
PCR technology, avoiding the construction of cDNA library and the use of sera from allergic
subjects for screening, which is time consuming [11-14]. An expressed sequence tagging (EST)
approach was applied to obtaining a large sampling and overview of expressed genomes of
several mite species [15], the EST approach involved the partial sequencing of random clones
selected from cDNA libraries, allowing the identification of allergens with homology to genes
from more distantly related species or even across taxonomic kingdoms.
The bacteria E. coli is the preferred expression system used for the production of recombinant
allergens, most of the house dust mite allergens have been expressed in this system with
success, allowing the molecular characterization [4, 5, 9, 10, 16-18]. The use of E. coli may result
in non-functional products expressed in inclusion bodies, and without the post-translational
modifications necessaries for their appropriate folding and biologic functions [19]. However,
by genetic engineering modified strains of this bacteria and novel expression vectors have been
obtained, which allow expression of heterologous protein in soluble form with functional
properties and high yield; Origami, Rosetta or BL21(DE3)-CodonPlus-pRIL and Rosetta-gami
are strains commercially available for obtain recombinants with some pos-translational
modifications [20]. In these E. coli strains the expression of allergens from the pollen Artemisia
vulgaris (Art v 3), the peanut (Ara h 2) and the beta-lactoglobulin from bovine have been
obtained in higher yield and solubility, and with structural and immunological properties
comparable to native allergens [21-23]. The GST tag used in the expression of the first re‐
combinant allergens have been replace for His x6 tag, which is shorter, the recombinant can
be analyzed without removing the tag due to the negligible effect on the properties of the
molecule, and several efficient purification systems are commercially available.
The eukaryotic expression system have the capacity of performing many of the post-transla‐
tional modifications including signal sequences, disulfide bond formation, and addition of
lipid and carbohydrates. A variety of eukaryotic expression systems like yeast, insect cells,
mammalian cells and plants are available. The yeast P. pastoris is easy to manipulate and
frequently used to express recombinant molecules with all the characteristics of their natural
counterparts, with a yield about 10 to 100 times higher than E. coli [24, 25]. Several recombinant
allergens have been obtained by expression in this yeast and their biologic properties demon‐
strated by different methods, this system have resulted especially practical when post-
translational modifications or biochemical activity exist [26-29]. The human cells have been
used to obtain the Phleum pretense allergen, Phl p 5, as a secreted or membrane-anchored
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protein and showed to be biologically active, with capacity to bind human IgE, to induce
mediator release from basophiles and to stimulate T cell proliferation [30]. A large percentage
of allergens are from plants, thus the plant-based expression systems are ideal for the produc‐
tion of certain recombinant allergens, which could have problems such as incorrect processing,
incorrect folding and insolubility when expressed in bacteria or other non-plant systems.
Thaumatin or thaumatin-like proteins, only when expressed in Nicotiana benthamiana result in
fully IgE-reactive proteins [31]. Interesting, expression in plants offers the opportunity for oral
delivery of recombinant allergens of non- plant origin as a therapeutic approach for mucosal
immunization for treating allergic diseases. Oral treatment of mice with squash extracts
containing virus-expressed Der p 5 allergen caused inhibition of both allergen-specific IgE
synthesis and airway inflammation [32], this plant-based edible vaccines is very promising.
3. Current vaccines for allergic diseases
Allergies are inflammatory diseases characterized by a Th2 biased response induced in atopic
individuals for exposure to allergens. The Th2 response is also induced by helminthes, which
occur in an environment characterized by the presence of IL-4, IL-5 and IL-13. Nuocytes [33,
34], basophiles [35] and type 2 multi-potent progenitor cells [36] seem to be an important source
of this cytokines and necessary for the development of allergic response. Allergen-specific IgE
antibodies produced by B cells bind to Fc epsilon receptor 1 (FcεRI) on basophiles or mast cells,
sensitizing them. After consecutive exposure, allergen binds to IgE on these cells leading to
the release of inflammatory mediators of immediate-type symptoms of allergic diseases and
paves the way for late-phase inflammatory responses caused by basophiles, eosinophils and
T cells. Allergen specific Th1, Th9, Th17 and Treg cells are also produced in this process [37, 38].
Allergen-specific immunotherapy (SIT) is the only curative and specific approach for treatment
of allergies [39, 40]. The current SIT consists of gradual administration of increasing amounts
of allergenic extract with the aim to avoid allergic symptoms associated to the exposition. The
induction of allergen tolerance is the essential immunological mechanisms of SIT, and involve
allergen-specific memory T and B-cell that lead to immune tolerance characterized by a specific
noninflammatory reactivity to a given allergen and prevention of new sensitizations and
progression of allergic disease. During the immunotherapy, different regulatory and effectors
components of the immune system are involved (Figure 1). Allergen tolerance is characterized
by the generation of two subgroups of Treg cells: FOXP3+ CD4+ CD25+ Treg cells and inducible
Treg cells [41]. T-regulatory type 1 (Tr1) cells have shown to play a major role in allergen
tolerance induced by SIT [42, 43]. The immunosuppressor mechanism of Treg cells is mediated
by the production of high level of anti-inflammatory cytokines IL-10 and TGF-β, although IFN-
γ could also be produced [44-46]. The expression of different subtypes of antibodies during
SIT is mediated by the activity of regulatory cytokines secreted by Treg cells; IL-10 is a potent
suppressor of allergen-specific IgE and simultaneously increases IgG4 production [42]. SIT
increase 10 to 100 folds the serum levels of allergen-specific IgG1 and IgG4 [43, 47]. The IgG4
seems to act as a blocking antibody that interacts with the allergen, avoiding interaction of
allergen with the IgE [48].
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Figure 1. Mechanism of allergen-specific immunotherapy. After vaccination, allergen is taken up by antigen present‐
ing cells leading to the differentiation of naïve T cells to inducible T regulatory cells. These cells with the thymus-de‐
rived FOXP3+CD4+CD25+ T regulatory cells, suppress allergic response by the following mechanisms. 1. Suppression of
mast cells, eosinophils and basophils. 2. Induction of IgG4 antibodies production from B cells that block the binding of
allergen with the IgE. 3. Suppression of effector T cells.
Vaccines composed of whole allergenic extract are complex mixtures of known and unknown
material, prepared directly from the allergen source, thus containing allergenic and non-
allergenic material and being difficult to standardize [49-51]. Some non-allergenic components
have been shown to prime a Th2 response [52], which offset the efficacy of this type of vaccines.
SIT with allergenic extract induce a variety of side effects ranging from local to systemic which
An Integrated View of the Molecular Recognition and Toxinology - From Analytical Procedures to Biomedical
Applications
294
in some case may be life-threatening [53]. Moreover, in some preparations the important
allergens are not well represented or they exhibit poor immunogenicity [51]. Administration
of whole allergenic extracts can induce new IgE specificities against allergens present which
were not recognized by the patient before treatment [54]. All these facts decrease the efficacy
and safety of the current allergen SIT [50]. Therefore, among new approaches to provide a
better treatment for allergic diseases is to develop vaccines based on preparations with a well-
defined composition, suitable for a good standardization and very low risk of anaphylaxis,
here the recombinant allergens or modification of these represent a good option, they show
characteristics that could allow to replace advantageously the whole allergenic extracts [55],
(Table 1).
Disadvantages of natural allergen extracts
Contain undefined components, some of which may promote allergic responses
Lack or contain low amounts of important allergens
Can be contaminated with unwanted materials or allergens from other sources
Cannot be tailored to the patient’s sensitization profile
May induce new sensitizations
Do not suit the international quality standards for vaccines
Cannot be compared between different products or batches
Do not allow the precise monitoring and investigation of mechanisms underlying treatment
Advantages of recombinant allergens
Represent molecules with defined physicochemical and immunologic properties that can be modified to
foster advantageous characteristics
Amounts can be easily controlled on the basis of mass units
Potencies and ratios can be exactly adjusted for each molecule
Represents pure molecules
Vaccines can be exactly tailored according to the patient’s sensitization profile
Fit the international quality standards for vaccines
Can be precisely compared to give consistent and reproducible products or batches
Allow the precise monitoring and investigation of mechanisms underlying treatment
Can be reproducible modified to suit different treatment strategies
Table 1. Advantages of recombinant allergens over traditional allergen extracts
From Molecular Cloning to Vaccine Development for Allergic Diseases
http://dx.doi.org/10.5772/52821
295
4. Recombinant allergens for diagnosis and allergen-specific
immunotherapy
Recombinant allergens may be obtained with the same structural and immunological prop‐
erties of its natural equivalent, therefore, the usefulness for diagnosis or immunotherapy is
guarantee. These can be expressed in large amounts in E. coli or eukaryotic systems at low cost
and without contaminants, and manipulating the nucleotide sequence of allergens followed
by molecular cloning and protein expression, modified version of allergens that preserve the
specific T cell recognition of the natural offending molecule but reduced allergenicity, can be
obtained providing a good material for allergen vaccine development.
4.1. Diagnosis of allergy
A more appropriate diagnostic of allergic diseases would be obtained by identification of the
particular molecules involved in allergic response, which could be done using purified wild
type or recombinant allergens in order to define the sensitization profile of each allergic subject,
the concept “Component-resolved diagnosis” was applied to this kind of diagnosis [56], that
would allow a “component-resolved immunotherapy”, in which only the allergens involved
in the sensitization are applied to an allergic subject, avoiding new sensitizations. There are
some illustrative examples of the goodness of this future practice: in skin tests with three
recombinant cherry allergens, rPru av 1, rPru av 3 and rPru av 4, the diagnosis of allergic
population could be obtained with sensitivity similar to that obtained with the allergenic
extract [57]. The population allergic to peanut was identified using three recombinant peanut
allergens (rAra h 1, rAra h 2 and rAra h 3) [58], in this study and another with celery allergens
was demonstrated that recombinant allergens improve the sensitivity of diagnosis compared
to allergenic extracts [58, 59]. In allergies with a high compromise of cross-reactivity such as
the pollen-related food allergy the power of in vitro testing using allergenic extracts is very low
[60]. Component resolved diagnosis with recombinant allergens result in excellent sensitivity,
when applied to allergy to hazelnut that shows cross-reactivity with pollen allergy. Vespid
allergy is characterized by cross-reactivity between hymenoptera species, and it has been
established that the true source of sensitization must be defined to ensure the efficacy of venom
immunotherapy [61]. Monsalve, et al. [62], found that in the Mediterranean regions, a compo‐
nent-resolved diagnosis for wasp allergy could be accurately defined using a mixture of the
allergens Ves v 1 and Ves v 5 from Vespula spp, and Pol d 1 and Pol d 5 from Polistes domini‐
lus. A combination of these four allergens is enough to differentiate the real causative venom
in at least 69% of the population. In allergy with a wide spectrum of sensitization profile as
the induced by Phleum pretense pollens, the use of recombinants is useful to establish a tailor
made immunotherapy approach [63]. A hybrid molecule composed of several segments of a
grass pollen allergen showed in skin tests on 32 allergic individuals that with only this molecule
all the allergic patients can be identified [64].
The technology of microarrays can be applied to target protein interactions and the serological
immune response to antigens [65]. Microarrays are highly useful for detecting all antibodies
isotypes and are a powerful tool for component-resolved diagnosis. The primary advantage
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of microarrays is that specific IgE to thousands allergens can be assayed in parallel with small
amounts of serum, at the same time, much less amount of allergen is required. The advantages
of protein microarrays to detect specific-antibodies against multiple targets have been taken
to develop component-based diagnosis tools. A microarray based test developed by VBC
Genomic and Phadia market as “ISAC” that uses a combination of 103 purified natural and
recombinant allergens from 47 species, is available in Europe, however, in the United States it
has not yet been approved for use by the US Food and Drug Administration and is available
only as a research tool (Available at: http://www.pirllab.com/). One of its potentials lies in the
recognition of individual patterns of IgE reactivity to protein families with homologues across
plant or animal species [66, 67]. When microarray test for diagnosis of birch and timothy allergy
were compared with other in vitro tests (Phadia CAP-FEIA and in-house ELISA), a correlation
greater than 0.9, with high sensitivity and specificity was obtained [68]. Latex allergy diagnosis
is well known to be confounded by a high rate of false positive results when using conventional
testing, and positive specific IgE results does not always mirror the clinical situation. A
combination of recombinant latex allergens (Hev b 1, Hev b 3, Hev b 5 and Hev b 6.02) on a
microarray, was enough to detect individuals allergic to latex with a sensitivity of 80%, and
allows discrimination between genuine allergy and sensitization [69]. Recently, a library of
419 overlapping peptides corresponding to the aminoacid sequence of peanut allergens Ara h
1, Ara h 2 and Ara h 3, printed onto glass slides to asses IgE reactivity, was evaluated as a
diagnostic tool that could replace the traditional used double-blind, placebo controlled food
challenge, that is time consuming, expensive, stressful for the patient and have the risk for
potentially life-threatening anaphylactic reaction [70, 71]. Based on the number or peptides
that bind IgE and the intensity of the reaction, was possible to distinguish peanut allergic and
peanut tolerant individuals with approximately 90% sensitivity and 95% specificity [71].
To evaluate the clinical significance and allergenicity of several recombinant allergens from
B. tropicalis and D. pteronyssinus in asthmatic patients from a tropical environment, IgE level
were determined in sera from 90 asthmatic patients and 10 healthy controls. In addition, SPT
was performed in a selected group of these patients [72]. Three recombinant allergens Der p
1, Der p 2, and Der p 10 were able to detect 93% of D. pteronyssinus allergic subjects. No adverse
reactions were observed in the allergic or control subjects who were skin tested. We can
conclude that recombinant allergens from B. tropicalis and D. pteronyssinus are useful for in
vitro and in vivo diagnostic tests of mite allergy diseases.
4.2. Allergen-specific immunotherapy
Allergen SIT with recombinant allergens was proposed when it was demonstrated that these
molecules have similar or the same biological properties of their natural counterparts [73, 74],
and the necessity of highly purified and well standardized allergens were required for
overcome the problems related to difficult standardization and management of the doses
observed with the whole allergenic extracts. A study with the recombinant pollen allergen Bet
v 1 (rBet v 1) demonstrated that immunotherapy with a single allergen is effective for the
specific treatment of allergy [75]. In a multicenter, double-blind, placebo-controlled clinical
trial, patients with history of birch pollen–related rhinoconjunctivitis were divided in four
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groups and treated for two years with rBet v 1, natural birch pollen extract, natural Bet v 1
(nBet v 1) or placebo, to compare the efficacy of each preparation for allergen-specific immu‐
notherapy. Treatment with rBet v 1 reduced symptoms of rhinoconjunctivitis and skin
reactivity induced by birch pollen, and showed to be safety without serious adverse events.
In contrast, one adverse event appears in the group treated with nBet v 1. Clinical improvement
and reduction of sensitivity were accompanied with marked increase in Bet v 1-specific IgG1,
IgG2 and IgG4 levels, which were higher in the rBet v 1-treated group than in nBet v 1-treated
group. Importantly, new IgE specificities were induced in 3 patients treated with birch pollen
extract, but in none of rBet v 1 or nBet v 1 treated patients.
In a placebo controlled immunotherapy study, a mixture of equimolar concentration of five
Phleum pretense allergens (Phl p 1, Phl p 2, Phl p 5a, Phl p 5b and Phl p 6) was administered via
subcutaneous for 18 months in patients with grass pollen–induced allergic rhinitis, to deter‐
mining efficacy and safety [43]. The immunotherapy showed a 36.5% lower median average
symptom score for active treatment compared with placebo and reduction in the need for
medication. By the first and second pollen season, improvement in quality of life scores was
present in the patients receiving active treatment. Active treatment induced IgG1 concentra‐
tions approximately 60-fold, peaking during the rusty 12 months of the study and IgG4 levels
showed a 4000 fold increase by the end of treatment. In contrast, after immunotherapy IgE
levels in the active treated group were significantly lower than placebo group. Only about 1%
of recombinant grass allergen injections led to systemic reactions. This was the first clinical
study of immunotherapy with a cocktail of 5 recombinant grass pollen allergens that showed
its clinical efficacy, good tolerance and strong induction of allergen specific IgG antibody
response.
5. Approaches for an immunotherapy of allergy based on modified
recombinant allergens
Several in vitro and in vivo assays indicate that allergy vaccines based on recombinant allergens
might have provide a safe and efficacious immunotherapy. However, recombinants with the
same amino acid sequence and similar allergenic activity as the natural allergens can elicit IgE-
mediated side effects, which are a major risk during allergen-specific immunotherapy. To
overcome this problem different approach have been designed to obtain molecules without or
reduced IgE reactivity [76]. Recombinant DNA technology has allowed the rational design and
production of well-defined modified allergens for this purpose. Hypo-allergens are molecules
derived from wild type allergen which exhibits reduced capacity to react with IgE antibodies
and low ability to induce IgE-mediated mast cells or basophile degranulation. They are
designed to reduce the risk of anaphylaxis during the course of immunotherapy, are molecules
with conserved T-cell epitopes that could be recognized by specific T lymphocytes to induce
a protective response against wild-type allergen.
Some allergens are present in the nature as a mix of several isoforms with high structural
homology but different IgE reactivity. The production by molecular cloning of natural isoforms
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with low IgE reactivity has been used to propose anti-allergy vaccines. Bet v 1.0401 and Bet v
1.1001 are isoforms that have lower IgE reactivity compared to the Bet v 1.0101 [77, 78].
Antibody response against Bet v 1.0401 is IgG4-specific and has low capacity to induce
basophile degranulation [79].
Hypo-allergens obtained by site-directed mutagenesis
The availability of multiple clones of recombinant allergens has facilitated the implementation
of site directed mutagenesis to obtain modified allergens for a better immunotherapy. There
are several examples of this approach that illustrate the potential use for the development of
new vaccines. Mouse allergic individuals are sensitized mainly against the major allergen Mus
m 1 a urinary protein belonging to the lipocalin superfamily which have typicall β-barrel fold,
that can be modified by mutation in the Tyr 120 residue, [80, 81]. Two hypo-allergenic variants
of this allergen; mutants 1Y120A, and Mus m 1-Y120F were expressed in P. pastoris with a
modified fold [82]. The mutants showed low capacity to react with IgE from allergic individ‐
uals and induced lower basophil degranulation than those induced by Mus m 1. In lympho‐
proliferation assays, using cells from mouse allergic individuals the mutants induced similar
lymphoproliferation to that induced by Mus m 1. In other study three variants of an allergen
from Artemisia (Art v 1), C22S, C47S and C49S [83], showed low IgE reactivity and mediator
release from RBL cells. In addition, the variants C49S and C22S induced significantly higher
T cell proliferative response in Artemisia allergic patients compared to the obtained with rArt
v 1, suggesting a potential utility for the immunotherapy of population allergic to Artemisia.
Using a different approach; mutations in residues involved in IgE binding but maintaining the
3D structure of the natural allergen, Spangforth et al. showed that mutants Gln45-Ser and
Pro108-Gly of allergen Bet v 1 displayed lower IgE reactivity and induced synthesis of IgG
antibodies that block the IgE reactivity against the natural Bet v1 [84]. Unlike the above
mentioned studies. The x-ray crystallography structures of the mutants were similar to the
natural allergen, indicating that the reduced IgE reactivity is not mediated by an inadequate
folding.
Hybrid proteins
Hybrid proteins are structures composed by two or more allergens or short portions of them
in only one molecule, in this way new interaction and bonds are generated, which may alter
the 3D structure and B epitopes characteristic of natural allergens. Decreasing the capacity of
IgE binding and mast cell degranulation. However, if these proteins conserve the T cell
epitopes, they could induce a protective response after allergen challenge. A single molecule
composed by different allergen polypeptides might reduce the number of molecules to be
included in the vaccine. Furthermore, hybrid molecules consisting of several copies of
homologous allergens or immunologically unrelated allergens could be used for the allergy
treatment in the patients who are sensitized to several allergens.
T. P. King, who constructed a molecule composed by two allergens from insect and demon‐
strated in vitro and mice models studies its anti-allergenic properties [85], pioneered the design
of hybrid proteins for allergen immunotherapy. Gonzales-Rioja et al. [86] obtained by PCR-
based engineering a molecule composed by two allergens from the pollen Parietaria judaica
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(Par j 1 and Par j 2) and demonstrated an important reduction of the IgE binding capacity by
skin prick test. Linhart et al. [87], constructed by PCR-based recombination, a nucleotide
sequence coding for principal allergens of timothy grass, Phl p 1, Phl p 2, Phl p 5 and Phl p 6.
The hybrid protein induced T cell proliferation similar to the equimolar mix of individual
allergens, the lymphocytes secreted regulatory and Th1 cytokines, IL-10 and IFN-γ, showing
capacity to induce immune deviation to a protective profile. In an allergic mouse model,
exposure to hybrid molecule induced the production of IgG that blocked mast degranulation.
However, this molecule was also capable to bind IgE from allergic individuals, and to induce
basophile degranulation, and high percentage of individuals allergic to timothy grass were
identified using this molecule, suggesting a potential as a diagnosis reagent.
The utility of hybrid proteins for the immunotherapy of house dust mite allergy have been
studied by Asturias, et al. [88], who designed two hybrid proteins composed by D. pteronyssi‐
nus allergens Der p 1 and Der p 2. The QM1 structure was composed of almost the whole
sequence of both allergens; a Der p 2-fragment from residues 5 to 123 at the N-terminus,
introducing point mutations on cysteine 8 and 119 to serine to avoid the formation of a
disulphide bridge, and a Der p 1-fragment from residues 4 to 222 at the C-terminus were joined.
The QM2 structure, was composed with the residues 1 to 73 and 74 to 129 of Der p 2, linked
to residues 5 to 222 of Der p 1. Western-blot assays with a serum pool from house dust mite
allergic patients showed decrease IgE reactivity of QM1, while QM2 showed no detectable IgE
binding capacity. The hypoallergenic properties of both hybrids were demonstrated by skin
tests. In vitro test with sample from allergic patients QM2 induced similar lymphoproliferation
that the induced by natural Der p 1 and Der p 2, whereas, QM1 induced higher proliferation.
It was demonstrated that antisera raised by immunization of mice with QM1 or QM2 lead to
the production of specific antibodies capable of blocking the binding of IgE reactivity to natural
allergens.
Recently, a hybrid protein composed of three allergens of Chenopodium album pollen, in the
order Che a 3-Che a 1-Che a 2, was constructed by using overlapping extension polymerase
chain reaction, expressed in E. coli BL21-CodonPlus(DE3)-RIL, to obtain a 46 kDa protein. Sera
from allergic patients showed lower IgE binding affinity to the hybrid molecule than the
mixture of recombinant allergens and the C. album pollen extract. Most of the allergic patients
showed positive skin test to a mixture of the three allergens, however, when tested with the
hybrid molecule allergic patients showed negative test or highly reduced weal area compared
to the mixture or to the pollen extract [89].
Mosaic proteins
Mosaic proteins are constituted by different segments of the same allergen, in different order
as they are present in the native molecule, such re-arrange generate new intra-molecular
interactions that alter B cell epitopes. A mosaic protein called P1m constructed with four
segments of the pollen allergen Phl p 1, showed lower IgE reactivity compared to the natural
allergen and was unable to induce histamine release from basophiles of allergic individuals.
However, this molecule conserved capacity to induce the proliferation of PBMCs. Immunized
rabbits expressed IgG antibodies that blocked the binding of Phl p 1 to the IgE and inhibit
histamine release from basophiles obtained from allergic individuals [90]. Other mosaic
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protein constructed with segments derived from Phl p 2 reassembled in altered order and
expressed as a trimer showed absence of IgE reactivity with sera from allergic patients.
Basophile activation and skin prick tests, showed reduction of the allergenicity of this molecule
compared to recombinant Phl p 2. Furthermore, IgG antibodies produced by immunized mice
were able to inhibit the binding of recombinant Phl p 2 to the IgE from allergic subjects [91].
Mosaic proteins have been studied as a potential vaccine for immunotherapy of birch allergy
[92] and house dust mite allergy [93]. A mosaic protein composed of reorganized segments of
Bet v 1 preserved the specific T cell epitopes and showed approximately 100-fold reduced
allergenic activity compared with recombinant Bet v 1 [94, 95] and induced specific IgG
antibodies inhibitors of IgE reactivity to Bet v1 of sera from patients with pollen allergy [96].
The mosaic protein exhibited none IgE reactivity and lower basophile activation. Furthermore,
immunization with Bet v 1 derivatives induced IgG antibodies that recognized Bet v 1 and
inhibited IgE binding to Bet v 1 [92].
Fragments of allergens or modification of these, might be poorly immunogenic because they
don´t have enough T cell epitopes capable to stimulate a protective immune response. An
increase of immunogenicity can be obtained when proteins are made as oligomers which
enhance the number of T cell epitopes in the molecule. It has been observed that immunoge‐
nicity of Bet v1 increase when obtained as oligomer [97, 98]. By dot-blot analysis and lympho‐
proliferative responses in PBMCs from birch pollen allergic patients, trimers of re-organized
segments of Bet v1 had lower capacity to bind IgE and enhanced capacity to stimulate
lymphoproliferation. The CD203c expression analysis showed reduced allergenicity of these
oligomers, and when administrated to mice in an immunization scheme, induced the produc‐
tion of high titer of IgG1 antibody, that inhibited human IgE binding to wild type Bet v 1 [99].
5.1. Molecules to target specific compartments or receptors
Targeting allergens to endoplasmic reticulum
It has been suggested that administration of higher allergen doses enhances the efficacy of
immunotherapy [100]. However, administration of high doses increases the risk of anaphy‐
laxis. One approach to overcome this problem is to deliver high doses of allergen to B and T
cells directly, thus providing higher effective doses to stimulate a protective response, and
avoiding the interaction of allergen with IgE antibodies [101]. An allergen vaccine for cat
allergy composed of the major cat allergen Fel d 1 fused to the HIV-derived translocation
peptide TAT was designed to mediate cytoplasmic uptake of extracellular proteins [102, 103].
Un modified version of this approach, denominated Modular Antigen Translocation (MAT)
technology have been developed [104, 105], which consists of allergen fused to a peptide, to
direct them to the cytosol, and a truncated human invariant chain (Ii), to target the protein to
MHC class II heterodimers assembled in the endoplasmic reticulum and thus circumventing
phagosomal uptake and degradation. The allergens Asp f 1, Der p 1, Bet v 1, PLA2 and Fel d
1 fused to MAT, induced lymphoproliferation of PBMCs stimulated ex vivo with low allergen
doses, induced the secretion of Th1 type cytokines and IL-10, and inhibit the production of
Th2 cytokines [105]. The cat allergen Fel d 1 fused to MAT (MAT- Fel d 1) when administered
directly to the inguinal lymph nodes of allergic mice, showed capacity to stimulate the
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production of high levels of IFN-γ and reduced levels of IL-4, compared to unmodified Fel d
1. Immunized mice expressed higher levels of IgG2a and showed protection against the
challenge of high doses of allergenic extract. Furthermore, MAT-Fel d 1 produced 100-fold less
degranulation and histamine release from basophiles compared to unmodified Fel d 1 [106].
Targeting allergens to receptors on dendritic cells
Dendritic cells (DCs) play an important role in the initiation and maintenance of T cell response
to allergens. Its role in the type of T cell response generated can be influenced by the maturation
state, while mature DCs induce effector T cell responses characterized by Th1 or Th2 response
[107], immature or semi-mature DCs are tolerogenic and have the ability to induce Tregs [108].
DCs express an array of Fc receptors which have the capacity to enhance allergen uptake
through internalization of allergen/antibody receptors complexes. When stimulated with
allergen, DCs express FcεRI, and activated a signal-transducing cascade involving immunor‐
eceptor tyrosine-based activation motif (ITAM), which result in increased production of
proinflammatory cytokines and chemokines, the induction of robust proliferation of allergen-
specific T cells and the development of allergic symptoms [109]. DCs also express the receptor
FcγRIIb that contains immunoreceptor tyrosine-based inhibition motif (ITIM) which induces
inhibitory signaling events. This receptor can co-aggregate with FcεRI that activating a
signaling cascade that culminates in inhibition of FcεRI signaling. Under these assumptions,
Zhu, D. et al. [110] designed a fusion molecule called GFD composed by a human IgG Fc
fragment linked to the allergen Fel d 1 by a flexible linker, with the aim to crosslink FcγRIIb
and FcεRI-bounded to the cat specific-IgE. In transgenic mice expressing human FcγRIIb and
FcεRI, sensitized with high doses of Fel d 1 specific-IgE and treated with several doses of GFD,
the challenge with Fel d 1 didn´t cause mast cell degranulation. A scheme of immunotherapy
with high doses of GFD resulted in the inhibition of allergic response against Fel d 1, pulmo‐
nary inflammation and skin reactivity in sensitized animals. Treated mice expressed IgG1
antibodies that blocked the binding of IgE to Fel d 1. When applied to mice sensitized to Fel d
1 in a scheme of rush immunotherapy, GFD blocked acute systemic allergic reaction, mast cell
degranulation, bronquial hyper-reactivity and pulmonary inflammation [111]. Recently, a
fusion protein composed of Fcγ chain and the Dermatophagoides farinae allergen, Der f 2, was
obtained and tested in a Der f 2 allergic murine model [112]. After treatment with the fusion
molecule, the levels of specific IgE to Der f 2, histamine and pro-inflammatory cytokines were
lowered in the Fcγ-Der f 2 treated allergic mice, compared to saline-treated allergic mice. These
results suggest that specific targeting of allergens to Fcγ receptors could be used as a strategy
in the development of antigen-specific immunotherapy for human allergic diseases.
A different molecular design was applied to target allergens to CD64 receptor on antigen
presenting cells; a fusion protein (H22-Fel d 1) composed by Fel d 1 linked to the variable region
of a monoclonal antibody anti-CD64 was designed to stimulate receptor internalization [113].
Flow cytometry analysis showed that H22-Fel d 1 binds to CD64 and reacted with IgE and IgG
with similar affinity compared to native allergen. In vitro assays demonstrated that the fusion
molecule stimulates the proliferation of T lymphocytes derived from allergic individuals and
the secretion of IL-5, IL-10 and IFN-γ [114]. Although H22-Fel d 1 is responsible of a positive
effect that could result in a protective response against allergen challenge, it also stimulated
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Th2 cytokines, in a mechanism in which the thymic stromal lymphopoietin (TSLP) cytokine
seems to be involved. This cytokine was shown to maintain and polarize circulating Th2 central
memory cells, including allergen-specific T cells [115]. Therefore, the usefulness of this kind
of preparation for allergy immunotherapy deserves further evaluation.
6. Insect sting allergy
Insect sting allergy are frequently caused by insect stings of the Apidae family (honeybees and
bumblebees), those from the Vespidae family (Vespula, Dolichovespula, Vespa and Polistes
genera) and, in some regions, also of the Formicidae family (ants). The sting can induce local
or systemic IgE-mediated hypersensitivity reactions that can be fatal [116]. Prevalence of
systemic reactions caused by insect stings are reported from 0,3% to 7,5% in the United States
and Europe [117, 118]. Up to one fifth of these subjects will eventually experience severe life-
threatening reactions. Hymenoptera venoms contain protein allergens, as well as non-
allergenic components, including toxins, vasoactive amines, acetylcholine, and kinins. Among
the multiple allergens in Hymenoptera venoms, two allergens are importan, the phospholipase
A2 from of honey bee (Apis mellifera) (Api m 1), and of the vespid venoms antigen 5 from
Vespula vulgaris (common wasp) denominated Ves v 5.
Several studies have demonstrated that immunotherapy for vespid allergy with venom
extracts is clinically effective and improve the quality of life and allergic symptoms. This
improvement is correlated to a significant decrease of total IgE levels, and increase in specific
IgG and IgG4 levels [119]. However, severe and life-threatening anaphylactic side effects may
be induced after the administration of crude allergen extracts [120].
One of the first attempts to obtain safer methods for immunotherapy of insect allergies was
made with allergen-derived peptides, containing T-cell epitopes. Peptides derived from the
bee allergen Api m 1, were applied to allergic individuals in different immunotherapy
schemes. In vitro and clinical phase trials showed that T cells from such patients showed
marked responsiveness to Api m 1 after long term treatment, a shift in the pattern of cytokine
secretion form a Th0 to a Th1 profile and increase in specific IgG4 levels [121-123].
The use of recombinant venom allergens for allergen specific immunotherapy has been
analyzed in animal models. Intranasal administration of the recombinant allergen from wasp
venom, rVes v 5, to mice prior to sensitization with natural allergens lead to a significant
reduction of the allergic reaction, reduction of specific IgE and IgG2a levels, increase of mRNA
levels of IL-10 and TGF-β. Pretreatment with the whole venom was less effective and caused
toxic side reactions, suggesting a favorable use of the recombinant protein [124]. Hybrid
proteins composed by allergens from bee venom have shown anti-allergenic properties in in
vitro and animal models [85]. A fusion protein composed of the two major bee venom allergens
Api m 1 and Api m 2 called Api m [1/2], showed reduced IgE reactivity of Api m [1/2] compared
with native allergens [125]. By the other hand, basophil degranulation and skin tests showed
that this fusion protein have hypo-allergenic properties. When applied subcutaneously, mice
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showed reduced specific IgE, IgG and IgG2 serum levels; demonstrating that such protein
represents a potential candidate for specific immunotherapy.
Naturally occurring variants of insect allergens could be also useful for specific immunother‐
apy. For example, the sting of Polybia scutellaris, a South American wasp, does not cause allergic
symptoms, however it has been proven that its venom contain Antigen 5 (Poly s 5), an analogue
of the allergen Pol s 5 [126, 127]. In mice, Poly s 5 induced IgG antibodies that cross react with
Pol a 5, but induced only minimal amounts of IgE and was poor inducer of basophil-mediator
release. Moreover, Poly s 5-specific serum showed a specific protective activity and was able
to inhibit Pol a 5-induced basophil degranulation [128].
Despite the promising results observed with recombinant and modified allergens in in vitro
and in vivo studies, more clinical phase studies need to be performed to demonstrate their
applicability for the allergen specific immunotherapy of insect allergy.
7. Recombinant allergy vaccines in clinical phase trials
Clinical trials with recombinant wild type allergens, and modified allergens have been
performed (Table 2). The first studies of allergen SIT with purified molecules were done with
peptides containing T cell epitopes either from the cat allergen Fel d 1 or from bee-venom-
derived phospholipase, administered without adjuvant [122, 123, 129-135]. Such peptides were
characterized by its low or none IgE binding capacity. However, they induced late phase
systemic side effects in different grades depending in the dose and route of administration
[129, 132, 134, 135]. Therapy with T cell peptides does not seem to influence IgE-mediated
allergic reactions, in fact, the majority of studies didn’t find evidence of changes in IgE levels
or IgE-mediated allergic inflammation furthermore, no induction of IgG response was noted.
Allergic patients under immunotherapy with hypoallergenic preparations of the major birch
pollen allergen Bet v 1 adsorbed to aluminum hydroxide as a pre-seasonal treatment for birch
pollen allergy in a clinical trial, expressed high levels of IgG1, IgG2 and IgG4 antibodies
directed against Bet v 1. These IgG antibodies blocked allergen-induced basophile degranu‐
lation and were associated with the ability of patients to tolerate higher allergen concentrations
in nasal provocation tests [136]. Immunotherapy with wild-type recombinant Bet v 1 has also
been examined for tablet-based sublingual immunotherapy in a phase II, multicenter, double-
blind, placebo-controlled, however, this study is still on course and only have been reported
good tolerability of the preparation with no serious adverse events and most side effects
observed locally [137].
In a clinical trial, a group of patients with grass pollen allergy was treated with a combination
of the major grass pollen allergens (Phl p 1, Phl p 2, Phl p 5a, Phl p 5b and Phl p 6) or with
placebo for subcutaneous immunotherapy [43]. Patients treated with the recombinants
improve their symptom medication score and had high IgG antibodies levels against natural
grass pollen allergens. Several studies of immunotherapy with these mixed allergens have
been performed and registered in the National Institutes of Health Clinical trial database (Table
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2). Recently, the immunomodulatory properties of MAT-Fel d 1 was studied in a phase I/IIa
clinical study [138]. In a randomized double blind trial, intralymphatic immunotherapy (ILIT)
with MAT-Fel d 1 in alum was compared with placebo, consisting in 3 injections of each
preparation for two months. MAT-Fel d 1 caused reduced skin reactions compared to equi‐
molar concentration of nFel d 1 by intradermal injection, which proved practically painless
and reduced drug-related adverse effects compared to placebo group. The IgG4 serum levels
in MAT-Fel d 1 treated group increased by a factor of 5.66, while IgG1 and IgE levels didn´t
change. After treatment, PBMCs from allergic individuals secreted higher levels of IL-10 when
challenged with rFel d 1. Immunotherapy with MAT-Fel d 1 showed to be successful because
patients increased their tolerance to nasal challenge, skin prick and dermal test, with cat dander
extract. Improvement of quality of life of patients treated with MAT-Fel d 1 was maintained
300 days after immunotherapy.
Allergen Allergen-based vaccine Rout of administration/Trials Year NIH Registrationnumber / Reference
Bet v 1 (Birch
pollen
allergen)
Bet v 1 trimer SCIT, DBPC, Phase II 2000 [125]
Bet v 1 fragments SCIT, DBPC, Phase II 2000 [125]
Bet v 1 folding variant
SCIT, OC, Phase II 2002 NCT00266526
SCIT, DBPC, Phase III 2004 NCT00309062
SCIT, DBPC, Phase III 2007 NCT00554983
SCIT, Immunological and histological
evaluation 2009 NCT00841516
Recombinant Bet v 1
SCIT, DBPC, Phase II 2002 NCT00410930
SLIT, Phase I 2006 NCT00396149
SLIT, Phase I 2007 NCT00889460
SLIT, DBPC, Phase II 2008 NCT00901914
Birch pollen
and apple
allergens
Bet v 1 / Mal d 1 SCIT, DBPC, Phase II 2011 NCT01449786
Phleum
pratense
allergens
Mix: Phl p 1, Phl p 2, Phl p 5a,
Phl p 5b and Phl p 6
SCIT, DBPC, Phase II 2002
SCIT, DBPC, Phase III 2004 NCT00309036
SCIT, DBPC, Phase II 2008 NCT0671268
SCIT, DBPC, Phase III 2009 NCT01353755
Phleum pratense peptide fused
to carries protein
SCIT, Phase II 2011 NCT01445002
SCIT, DBPC, Phase IIb 2012(Initiating) NCT01538979
Peanut
allergens
Modified Ara h 1, Ara h 2, Ara h
3 Rectal 2009 NCT00850668
NCT numbers identify the trials that are registered in the National Institutes of Health Clinical trial database.
DBPC, Double-blind, placebo-controlled; OC, open controlled; SCIT, subcutaneous immunotherapy; SLIT, sublingual
immunotherapy.
Table 2. Currently ongoing recombinant molecules development for allergen specific immunotherapy.
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The National Institutes of Health’s clinical trial database contain information about a study
that intends to use the recombinant modified peanut allergens Ara h 1, Ara h 2 and Ara h 3
encapsulated in heat/phenol-killed E.coli. This phase I study should recruit healthy volunteers
to receive four scaling doses of the peanut preparation rectally at weekly intervals. The major
allergen of ragweed pollen Ambrosia artemisifolia, Amb a 1, was conjugated to CpG oligonu‐
cleotides to reduce the allergenic activity of Am b a 1 and to shift the specific Th2 response to
a Th1 response, mediated by the binding of CpG with toll-like receptor 9. Allergic individuals
treated with the conjugated vaccine showed reduction in eosinophilia and the number of IL-4-
producing cells, and increased numbers of IFN-γ-producing cells compared to placebo-treated
patients [139]. Furthermore, increase of regulatory T cells infiltration in the nasal mucosa was
found after the course of immunotherapy [140].
8. Some considerations for a recombinant based mite allergy vaccine
The prevalence and severity of allergic diseases such as asthma and rhinitis have increased in
recent decades [141], and house dust mite allergy is one of the most common allergies world-
wide which affect more than 50% of allergic patients [142]. Several house dust mites species
co-exist in tropical and subtropical regions, however in these places the species B. tropicalis
and D. pteronyssinus are the most prevalent and a high percentage of allergic population is
sensitized to allergens from these two species [143, 144], [72, 145]. Analysis if house dust mite
extracts have shown that over 20 different proteins can induce IgE antibodies in allergic
populations and several of them show cross-reactivity with allergens from other mite species.
Most of them have been obtained and characterized by molecular cloning and its IgE reactivity
analyzed [4]. However, it has been suggested that the majority of mite-allergic subjects elicit
an IgE response to around five components of allergenic extracts [146, 147], and some of them
may be cross-reactive. Therefore, and admixture of few allergens, including those species-
specific and cross-reactive, could replace the crude allergenic extract for diagnostic and
therapeutic purpose. Several studies indicate that a combination of allergens from group 1 and
2 bind to more than 50% of specific-IgE from allergic population, groups 5 and 7 are next in
importance [148-150]. It has been reported from Middle Europe that more than 95% of mite
allergic patients were mainly sensitized to Der p 1 and Der p 2, and that diagnostic test
containing these allergens plus the highly cross-reactive allergen Der p 10 may improve the
diagnostic selection of patients for immunotherapy with D. pteronyssinus extracts [151]. Other
allergens are important given their cross-reactivity and the role that they play in tropical
populations, as the case of group 10 and 12 [16, 152]. Results from our research group suggested
that a combination of these allergens from D. pteronyssinus might be sufficient to identify
almost all our mite allergic population [72] (Figure 2).
Recent studies with hybrid proteins composed by the most important pollen allergens, have
suggested that preparations based on molecules containing the B-epitope spectrum of
allergenic extracts could be useful for the diagnosis and allergen-specific immunotherapy [64,
86, 87]. We have engineered several fusion proteins composed by segments of different
allergens of B. tropicalis and D. pteronyssinus with the aim to obtain preparations useful for the
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diagnosis and immunotherapy of allergies caused by house dust mites. The coding sequences
of each molecule was cloned into expression vectors and then expressed in E. coli fused to
6xHis tag for further purification by affinity chromatography. One of these proteins denomi‐
nated DPx4, consistent of different segments of allergens from D. pteronyssinus (Der p 1, Der
p 2, Der p 7 and Der p 10), showed a 41% frequency of IgE reactivity in sera from mite allergic
patients sensitized to D. pteronyssinus and the specific IgE levels against the recombinant were
significantly lower than those against the whole allergenic extract from mites. Basophil
activation test showed that DPx4 has lower capacity to induce basophile degranulation
compared to the allergenic extract. These results suggest that the fusion protein have a
hypoallergenic profile, and that is a good candidate for develop a vaccine with potential use
for allergen specific immunotherapy of mite allergy [153]. Further in vitro studies as well as
experiment with animal models are in progress to support this application.
Figure  2.  Frequency  of  IgE  reactivity  to  allergens  from  B.  tropicalis  and  D.  pteronyssinus  in  asthmatic  patients
(From Ref 72).
9. Conclusions
For several years the allergen-specific immunotherapy has been successfully done with natural
allergenic extracts. However, they are complex mixtures difficult to standardize that might
cause local or systemic reactions, compromising the patient’s life. In the last decades, the
molecular cloning applied to the study of allergens has allowed obtaining several recombinant
allergens from different sources, and their biological and molecular properties elucidated.
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Component based diagnosis and immunotherapy is now possible by the availability of several
recombinant allergens, which represents the best approach to achieve the most efficacious
diagnosis and treatment of allergies, based on the sensitization profile and of each patient.
Vaccines for allergic diseases based on recombinant allergens or modification of these, that
could modulate the immune response against natural allergens toward a protective response,
have been proposed. Hypoallergenic molecules obtained by molecular cloning, in different
versions like hybrid molecules, oligomers, mosaic proteins or variants obtained by site-
directed mutagenesis have been developed and studied by in vitro test, animal model and
clinical trial in humans, indicating potential beneficial use in the near future. Recombinant
allergens coupled to carriers for directing the molecule to specific cells or intracellular
compartments, preventing unwanted side effects and increasing the specificity of the immune
response have been explored.
The promising results showed by in vitro and animal models studies have encouraged the
design of clinical phase trials where recombinant allergens have demonstrated their good
potential to provide a more efficacious and safe diagnosis and allergen-specific immunother‐
apy. In the last years, the number of clinical phase trials designed and registered in the National
Institutes of Health Clinical trial database is increasing. This tendency suggests that in few
years several vaccines based on recombinant allergens could be commercially available in
replacement of the traditional allergenic extract.
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